Updates are available Correction dated 2023-10-16
Click to view Correction: https://doi.org/10.1038/s41593-023-01489-z
-
Authors
Zhou, Jessica L. https://orcid.org/0000-0002-4131-0756
de Guglielmo, Giordano https://orcid.org/0000-0002-4782-7430
Ho, Aaron J.
Kallupi, Marsida https://orcid.org/0000-0002-8688-709X
Pokhrel, Narayan
Li, Hai-Ri
Chitre, Apurva S.
Munro, Daniel https://orcid.org/0000-0002-0724-218X
Mohammadi, Pejman
Carrette, Lieselot L. G. https://orcid.org/0000-0002-5217-2774
George, Olivier https://orcid.org/0000-0002-3700-5003
Palmer, Abraham A. https://orcid.org/0000-0003-3634-0747
McVicker, Graham https://orcid.org/0000-0003-0991-0951
Telese, Francesca https://orcid.org/0000-0003-3877-0628
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (U01DA050239)
U.S. Department of Health & Human Services | NIH | Center for Information Technology (F31DA056226, U01DA043799, P50DA037844, R01GM140287)
Brain and Behavior Research Foundation
- License Information
-
More Information
Article History
Received: 3 September 2022
Accepted: 6 September 2023
First Online: 5 October 2023
Change Date: 16 October 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41593-023-01489-z
Competing interests
: A.A.P. holds a patent related to the use of GLO1 inhibitors (US20160038559, active). The inventors of this patent are A. Palmer and M. Distler. All other authors declare no competing interests.
